Human NLRP1 and NLRP3 interact to drive inflammation in inflammosomopathies and inflammatory diseases

Read full text
Authors: Juan Miguel Suarez-Rivero, Inés Muela‐Zarzuela, Antonio Astorga-Gamaza, Rosa Antón, Sofia Bali, Joaquin Tamargo‐Azpilicueta, Alejandra Guerra‐Castellano, Raquel de la Varga‐Martínez, Daniel García-Cuesta, Irene Díaz‐Moreno, Łukasz A. Joachimiak, Javier Oroz
+2 more Alberto Sanz, Mario David Cordero
Cited by: 0
References: 32

Abstract

Abstract Inflammasomes are multiprotein complexes that form and activate after exposure to pathogenic microbes and host danger signals that trigger an inflammatory response. Although NLRP1 and NLRP3 inflammasomes share structural similarities and can be activated by similar stimuli, no evidence of heterotypic inflammasome assemblies has been reported. Here, we identify a unique interaction between NLRP1 and NLRP3 in human cells, forming a hybrid inflammasome, to drive inflammation. NLRP1 is essential for this hydrid inflammasome activation and NLRP3-mediated Caspase-1 activation and release of IL-1β and IL-18. The presence of the heterocomplex inflammasome was confirmed in blood samples from patients after kidney transplantation and is associated with inflammatory responses driven by NLRP3 and MEFV mutations that cause inflammasomopathies. Our findings reveal an unexpected level of intricacy in inflammasome composition, pinpointing hybrid targets that may pave the way for innovative pharmacological treatments for inflammatory disorders. Significance Statement Previous findings showed interactions between NLRP3 and NLRC4 or NLRP3 and NLRP11 showing that would be possible the interaction of the inflammasomes as supercomplexes and not working alone. Now, we show a new inflammasome heterocomplex inflammasome between NLRP1 and NLRP3 which is associated to the inflammatory profile in autoimmune diseases patietns and transplanted patients. These findings could open a new research topic for the design of dual inflammasomes inhibitors.

Fields of Study & Subjects

Inflammasome and immune disorders Immune Response and Inflammation IL-33 ST2 and ILC Pathways

Publication details

Journal / source
bioRxiv (Cold Spring Harbor Laboratory)
Publication date
29 January 2026
Document type
Preprint